Search results for "Movement disorder"

showing 10 items of 79 documents

MOTOR DYSFUNCTION OF THE "NON AFFECTED" LOWER LIMB: A KINEMATIC COMPARATIVE STUDY BETWEEN HEMIPARETIC STROKE AND TOTAL KNEE PROSTHESIZED PATIENTS

2009

In patients with hemispheric stroke, abnormal motor performances are described also in the ipsilateral limbs. They may be due to a cortical reorganization in the unaffected hemisphere; moreover, also peripheral mechanisms may play a role. To explore this hypothesis, we studied motor performances in 15 patients with hemispheric stroke and in 14 patients with total knee arthroplasty, which have a reduced motility in the prosthesized leg. Using the unaffected leg, they performed five superimposed circular trajectories in a prefixed pathway on a computerized footboard, while looking at a marker on the computer screen. The average trace error was significantly different between the groups of pat…

Malemedicine.medical_specialtyNeurologyKnee JointPostureDermatologyKinematicsEfferent PathwaysTotal kneeFunctional LateralityDisability EvaluationPhysical medicine and rehabilitationSTROKE TOTAL KNEE PROSTHESIZEDMedicineHumansMuscle SkeletalStrokeGaitGait Disorders NeurologicNeuroradiologyAgedLegMovement DisordersReflex Abnormalbusiness.industrySettore MED/34 - Medicina Fisica E RiabilitativaGeneral MedicineMiddle Agedmedicine.diseaseProprioceptionPeripheralBiomechanical PhenomenaParesisStrokePsychiatry and Mental healthHemiparesisPhysical therapySomatosensory DisordersFemaleNeurology (clinical)Neurosurgerymedicine.symptombusinessKnee ProsthesisMechanoreceptors
researchProduct

Nitric oxide modulation of the basal ganglia circuitry: therapeutic implication for Parkinson's disease and other motor disorders.

2011

Several recent studies have emphasized a crucial role for the nitrergic system in movement control and the pathophysiology of the basal ganglia (BG). These observations are supported by anatomical evidence demonstrating the presence of nitric oxide synthase (NOS) in all the basal ganglia nuclei. In fact, nitrergic terminals have been reported to make synaptic contacts with both substantia nigra dopamine-containing neurons and their terminal areas such as the striatum, the globus pallidus and the subthalamus. These brain areas contain a high expression of nitric oxide (NO)-producing neurons, with the striatum having the greatest number, together with important NO afferent input. In this pape…

Parkinson's diseaseMovement disordersSubstantia nigraStriatumNitric OxideSettore BIO/09 - FisiologiaBasal GangliaBasal Ganglia DiseasesBasal gangliamedicineAnimalsHumansMovement disordersPharmacologyMovement Disordersbusiness.industryGeneral NeuroscienceNITRIC OXIDE BASAL GANGLIASubthalamusNitric oxideParkinson Diseasemedicine.diseasemedicine.anatomical_structureGlobus pallidusnervous systemDyskinesiaBasal gangliaParkinson’s diseasemedicine.symptomNerve NetbusinessNeuroscienceCNSneurological disorders drug targets
researchProduct

New insights in the neurological phenotype of aceruloplasminemia in Caucasian patients

2017

Abstract Introduction The diagnosis aceruloplasminemia is usually made in patients with advanced neurological manifestations of the disease. In these patients prognosis is poor, disabilities are severe and patients often die young. The aim of our study was to facilitate recognition of aceruloplasminemia at a disease stage at which treatment can positively influence outcome. Currently, the neurological phenotype of aceruloplasminemia has been mainly described in Japanese patients. This ‘classical’ phenotype consists of cerebellar ataxia, hyperkinetic movement disorders and cognitive decline. In this study we describe the spectrum of neurological disease in Caucasian patients. Methods Data on…

0301 basic medicineAdultMalemedicine.medical_specialtyPediatricsAtaxiaMovement disordersBiologyWhite People03 medical and health sciencesNeurological manifestation0302 clinical medicinePhenotypic variabilitymedicineAceruloplasminemiaHumansCognitive declineAceruloplasminemiaPsychiatryDystoniaCerebellar ataxiaParkinsonismCeruloplasminChoreaNeurodegenerative DiseasesMiddle Agedmedicine.diseaseIron Metabolism DisordersPedigree030104 developmental biologyPsychiatric changesPhenotypeNeurologyFemaleNeurology (clinical)Geriatrics and Gerontologymedicine.symptomNervous System DiseasesSettore M-EDF/01 - Metodi E Didattiche Delle Attivita' Motorie030217 neurology & neurosurgeryFollow-Up Studies
researchProduct

Factors influencing psychological well-being in patients with Parkinson's disease.

2017

Background Both motor and non-motor symptoms could contribute to significant deterioration of psychological well-being in patients with Parkinson's disease (PD). However, its assessment has been only indirectly evaluated using tools based on health-related quality of life (HRQoL), such as the PDQ-39 scale. Objectives To evaluate psychological well-being in PD using a specific tool of assessment, the Psychological Well-being Scale (PWS), and its clinical correlates. Methods This article reports data of patients' perception of health state, as measured by means of the PWS, from an epidemiological, cross-sectional study conducted in Italian PD patients (FORTE Study). We tested possible relatio…

Genetics and Molecular Biology (all)MaleParkinson's diseaseEmotionsPoison controlSocial Scienceslcsh:MedicinePathology and Laboratory MedicineBiochemistrySeverity of Illness IndexAged; Depression; Fatigue; Female; Humans; Italy; Male; Middle Aged; Parkinson Disease; Psychiatric Status Rating Scales; Quality of Life; Severity of Illness Index; Surveys and Questionnaires; Biochemistry Genetics and Molecular Biology (all); Agricultural and Biological Sciences (all)0302 clinical medicineMathematical and Statistical TechniquesQuality of lifeSurveys and QuestionnairesMedicine and Health SciencesMedicinePsychologySurveys and Questionnaire030212 general & internal medicinelcsh:ScienceDepression (differential diagnoses)FatigueMultidisciplinaryMovement DisordersDepressionNeurodegenerative DiseasesParkinson DiseaseMiddle AgedPsychiatric Status Rating ScalehumanitiesNeurologyItalyPhysical SciencesFemaleStatistics (Mathematics)Clinical psychologyResearch ArticleHumanResearch and Analysis Methods03 medical and health sciencesSigns and SymptomsDiagnostic MedicineSeverity of illnessInjury preventionMental Health and PsychiatryHumansStatistical MethodsAgedPsychiatric Status Rating Scalesparkinson's disease quality of lifeAnalysis of VarianceBiochemistry Genetics and Molecular Biology (all)business.industryMood Disorderslcsh:RBeck Depression InventoryBiology and Life Sciencesmedicine.diseaseHealth CareAgricultural and Biological Sciences (all)Psychological well-beingAged; Depression; Fatigue; Female; Humans; Italy; Male; Middle Aged; Parkinson Disease; Psychiatric Status Rating Scales; Quality of Life; Severity of Illness Index; Surveys and QuestionnairesQuality of Lifelcsh:QbusinessSleep Disorders030217 neurology & neurosurgeryMathematicsPLoS ONE
researchProduct

[Exercices program and rehabilitation of motor disorders in Parkinson's disease].

2000

International audience; As long as motor disorders are controlled by DOPAtherapy, exercise programs and rehabilitation would not appear to be essential for patients suffering from Parkinson's disease. Such measures do become necessary however when secondary occurrence of motor decline develops. Physical medicine and rehabilitation have not been really involved in Parkinson's disease and few articles have assessed the value of these programs. In fact, controlled randomized studies have faced two kinds of methodological difficulties, those due to rehabilitation practices, and those due to Parkinson's disease specificity, especially similarities between groups for Hoehn and Yahr stage at study…

MESH: HumansMovement DisordersMESH : Humans[SDV.NEU.SC]Life Sciences [q-bio]/Neurons and Cognition [q-bio.NC]/Cognitive SciencesParkinson DiseaseMESH : Exercise TherapyExercise Therapy[ SDV.NEU.SC ] Life Sciences [q-bio]/Neurons and Cognition [q-bio.NC]/Cognitive SciencesMESH : Parkinson DiseaseMESH : Physical Therapy ModalitiesMESH : Movement DisordersMESH: Exercise TherapyHumans[SDV.NEU.SC] Life Sciences [q-bio]/Neurons and Cognition [q-bio.NC]/Cognitive SciencesMESH: Movement DisordersMESH: Parkinson DiseasePhysical Therapy ModalitiesMESH: Physical Therapy ModalitiesRevue neurologique
researchProduct

Cross-frequency coupling between gamma oscillations and deep brain stimulation frequency in Parkinson's disease.

2020

Abstract The disruption of pathologically enhanced beta oscillations is considered one of the key mechanisms mediating the clinical effects of deep brain stimulation on motor symptoms in Parkinson’s disease. However, a specific modulation of other distinct physiological or pathological oscillatory activities could also play an important role in symptom control and motor function recovery during deep brain stimulation. Finely tuned gamma oscillations have been suggested to be prokinetic in nature, facilitating the preferential processing of physiological neural activity. In this study, we postulate that clinically effective high-frequency stimulation of the subthalamic nucleus imposes cross-…

MaleDeep brain stimulationmedicine.medical_treatmentDeep Brain StimulationStimulationcross-frequency couplingsource analysis610 Medicine & healthArticlePremotor cortexvolume of tissue activatedSubthalamic NucleusCerebellumGamma RhythmNeural PathwaysmedicineGamma RhythmHumans610 Medicine & healthAgedMovement DisordersSupplementary motor areaResting state fMRIChemistryMotor CortexElectroencephalographyParkinson DiseaseMiddle AgedSubthalamic nucleusmedicine.anatomical_structureFemaleNeurology (clinical)gamma oscillationsBeta RhythmNeuroscienceAlgorithmsMotor cortex
researchProduct

Myocardial 123metaiodobenzylguanidine uptake in genetic Parkinson's disease.

2008

Myocardial (123)Metaiodobenzylguanidine (MIBG) enables the assessment of postganglionic sympathetic cardiac innervation. MIBG uptake is decreased in nearly all patients with Parkinson's disease (PD). Our objective was to evaluate MIBG uptake in patients with genetic PD. We investigated MIBG uptake in 14 patients with PD associated with mutations in different genes (Parkin, DJ-1, PINK], and leucine-rich repeat kinase 2 -LRRK2), in 15 patients with idiopathic PD, and 10 control subjects. The myocardial MIGB uptake was preserved in 3 of the 4 Parkin-associated Parkinsonisms, in I of the 2 patients with DJ-1 mutations, in 1 of the 2 brothers with PINK] mutations, in 3 of the 6 unrelated patient…

AdultMalemedicine.medical_specialtyParkinson's diseaseGenotypeUbiquitin-Protein LigasesDNA Mutational AnalysisProtein Deglycase DJ-1PINK1Gene mutationProtein Serine-Threonine Kinasesmedicine.disease_causeLeucine-Rich Repeat Serine-Threonine Protein Kinase-2Severity of Illness IndexParkinCentral nervous system diseaseDiagnosis DifferentialDegenerative diseaseParkinsonian DisordersInternal medicineSurveys and QuestionnairesmedicineHumansPoint MutationPromoter Regions GeneticGenetic PD Myocardial scintigraphyOncogene ProteinsTomography Emission-Computed Single-PhotonMutationMovement Disordersbusiness.industryMyocardiumIntracellular Signaling Peptides and ProteinsParkinson DiseaseGalvanic Skin ResponseMiddle Agedmedicine.diseaseLRRK2nervous system diseases3-IodobenzylguanidineEndocrinologyNeurologySettore MED/26 - NeurologiaFemaleNeurology (clinical)RadiopharmaceuticalsbusinessProtein KinasesMovement disorders : official journal of the Movement Disorder Society
researchProduct

Health-Related Quality of Life Is Severely Affected in Primary Orthostatic Tremor

2018

International audience; Background: Primary orthostatic tremor (POT) is a movement disorder characterized by unsteadiness upon standing still due to a tremor affecting the legs. It is a gradually progressive condition with limited treatment options. Impairments in health-related quality of life (HQoL) seem to far exceed the physical disability associated with the condition.Methods: A multi-center, mixed-methodology study was undertaken to investigate 40 consecutive patients presenting with POT to four movement disorder centers in France. HQoL was investigated using eight quantitative scales and a qualitative study which employed semi-structured interviews. Qualitative data were analyzed wit…

medicine.medical_specialtyPhysical disabilityQualitative propertyprogressiveFear of fallinglcsh:RC346-429Grounded theory03 medical and health sciences0302 clinical medicineQuality of life (healthcare)Physical medicine and rehabilitationMedicine030212 general & internal medicinelcsh:Neurology. Diseases of the nervous systemOriginal Researchbusiness.industryMultimethodology3. Good healthprimary orthostatic tremorhealth-related quality of lifeNeurology[ SDV.NEU ] Life Sciences [q-bio]/Neurons and Cognition [q-bio.NC][SDV.NEU]Life Sciences [q-bio]/Neurons and Cognition [q-bio.NC]movement disorderNeurology (clinical)Thematic analysismedicine.symptombusinessmixed-method methodology030217 neurology & neurosurgeryNeuroscienceQualitative research
researchProduct

Nanoparticulate Systems for Drug Delivery and Targeting to the Central Nervous System

2010

Brain delivery is one of the major challenges for the neuropharmaceutical industry since an alarming increase in brain disease incidence is going on. Despite major advances in neuroscience, many potential therapeutic agents are denied access to the central nervous system (CNS) because of the existence of a physiological low permeable barrier, the blood-brain barrier (BBB). To obtain an improvement of drug CNS performance, sophisticated approaches such as nanoparticulate systems are rapidly developing. Many recent data demonstrate that drugs could be transported successfully into the brain using colloidal systems after i.v. injection by several mechanisms such as endocytosis or P-glycoprotei…

Movement disorders/Parkinson’s diseaseDrug CarriersPolymersSurface PropertiesReviewsBrainAlzheimer's diseaseMultiple sclerosisDrug Delivery SystemsMovement disorders/Parkinson's diseaseSettore CHIM/09 - Farmaceutico Tecnologico ApplicativoLiposomesNeuropsychopharmacology.AnimalsHumansNanoparticlesMultiple sclerosiParticle SizeNeuropsychopharmacologyAlzheimer’s diseaseMicellesCentral Nervous System Agents
researchProduct

The Clinical and Molecular Spectrum of GM1 Gangliosidosis

2019

Objective To evaluate the clinical presentation of patients with GM1 gangliosidosis and to determine whether specific clinical or biochemical signs could lead to a prompt diagnosis. Study design We retrospectively analyzed clinical, biochemical, and genetic data of 22 patients with GM1 gangliosidosis from 5 metabolic centers in Germany and Austria. Results Eight patients were classified as infantile, 11 as late-infantile, and 3 as juvenile form. Delay of diagnosis was 6 ± 2.6 months in the infantile, 2.6 ± 3.79 years in the late-infantile, and 14 ± 3.48 years in the juvenile form. Coarse facial features, cherry red spots, and visceromegaly occurred only in patients with the infantile form. …

Malemedicine.medical_specialtyMovement disordersAdolescentGenotypeUrinary systemDNA Mutational AnalysisDiseaseGastroenterologyYoung Adult03 medical and health sciences0302 clinical medicineGermany030225 pediatricsInternal medicineGenotypemedicineHumans030212 general & internal medicineChildRetrospective StudiesDystoniaGangliosidosis GM1Coarse facial featuresbusiness.industryIncidenceInfantDNAbeta-Galactosidasemedicine.diseaseDysphagiaPhenotypeAustriaChild PreschoolMutationPediatrics Perinatology and Child HealthATP-Binding Cassette TransportersFemalemedicine.symptombusinessVisceromegalyFollow-Up StudiesThe Journal of Pediatrics
researchProduct